Mason, Ashley E.
Kasl, Patrick
Soltani, Severine
Green, Abigail
Hartogensis, Wendy
Dilchert, Stephan
Chowdhary, Anoushka
Pandya, Leena S.
Siwik, Chelsea J.
Foster, Simmie L.
Nyer, Maren
Lowry, Christopher A.
Raison, Charles L.
Hecht, Frederick M.
Smarr, Benjamin L.
Funding for this research was provided by:
Medical Technology Enterprise Consortium (MTEC-20-12-COVID19-D.-023)
#StartSmall Foundation (7029991)
Oura Health Oy (134650)
Article History
Received: 26 September 2023
Accepted: 6 January 2024
First Online: 5 February 2024
Change Date: 29 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-60565-x
Competing interests
: CLR serves as a consultant for Usona Institute, Novartis, Emory Healthcare and Biogen/Sage. AEM and BLS have received financial renumeration from Oura Ring, Inc. for consulting. BLS has a financial interest in Oura Ring, Inc. CAL is Cofounder, Board Member, and Chief Scientific Officer of Mycobacteria Therapeutics Corporation, and is a member of the faculty of the Integrative Psychiatry Institute, Boulder, Colorado, the Institute for Brain Potential, Los Banos, California, and Intelligent Health Ltd, Reading, UK. All other authors do not have any competing interests to declare.